New York, USA, Sept. 05, 2022 (GLOBE NEWSWIRE) -- Refractory Multiple Myeloma Pipeline Analysis of 80+ therapies: Key Pharma Players Set to Develop Novel Therapies
The increasing incidence, rise in healthcare investments and a number of diagnoses among patients are driving the growth of the market. Major players that are developing potential therapies in the late stage of development include Janssen Research & Development, LLC, MorphoSys/ I-Mab Biopharma, Rapa Therapeutics, Arcellx, Inc., Novartis, and several others.
DelveInsight’s 'Refractory Multiple Myeloma Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline refractory multiple myeloma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the refractory multiple myeloma pipeline domain.
Key Takeaways from the Refractory Multiple Myeloma Pipeline Report
- DelveInsight’s refractory multiple myeloma pipeline report depicts a robust space with 70+ active players working to develop 80+ pipeline therapies for refractory multiple myeloma treatment.
- Key refractory multiple myeloma companies such as NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, Amgen, Pfizer, Rapa Therapeutics, Arcellx, Inc., Gilead Sciences, Novartis, Celgene Corporation, Genmab, Harpoon Therapeutics, Cytovia Therapeutics, Ichnos Sciences, Poseida Therapeutics, Allogene Therapeutics, Seagen Inc., Regeneron Pharmaceuticals, CFT7455, C4 Therapeutics, CARsgenTherapeutics Co.,Ltd, CELLECTAR BIOSCIENCES, INC., Nektar Therapeutics, iTeos Therapeutics, CASI Pharmaceuticals, Fate Therapeutics, Actinium Pharmaceuticals, Inc., Molecular Templates, Inc., NexImmune, Inc., LAVA Therapeutics, Sorrento Therapeutics, Chimerix, Ascentage Pharma Group Inc., Keymed Biosciences, MiNK Therapeutics, and others are evaluating new drugs for refractory multiple myeloma to improve the treatment landscape.
- Promising refractory multiple myeloma pipeline therapies in various stages of development include NEXI 002, AMG-701, ABBV 453, ALLO-605, PBCAR269A, TAK-981, ABBV-383, ORIC-533, agenT-797, ION251, UCARTCS1A, Y150, Talquetamab, Ipilimumab, LAVA-051, Felzartamab, Elranatamab, RAPA-201, CART-ddBCMA, Magrolimab, PHE885, Marizomib, Teclistamab, HPN-217, CYT-338, ISB 1342, P-BCMA-ALLO1, ALLO-715, ALLO-605, SEA-BCMA, REGN5458, NKTR-255, Iopofosine, EOS-448, CID-103, FT538, MT-0169, NEXI-002, LAVA-051, STI-6129, ONC201, APG-2575, CM336, agenT-797, and others.
- In August 2022, Ipsen announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as ‘an Ipsen company’ at deal close.
- In June 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for talquetamab for the treatment of adult patients with relapsed or refractory multiple myeloma.
- In June 2021, AbbVie and Teneobio, Inc. announced that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma (R/R MM).
Request a sample and discover the recent advances in refractory multiple myeloma treatment drugs @ Refractory Multiple Myeloma Pipeline Report
The refractory multiple myeloma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage refractory multiple myeloma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the refractory multiple myeloma clinical trial landscape.
Refractory Multiple Myeloma Overview
Multiple myeloma is a type of cancer that begins in a type of white blood cell known as a plasma cell. It's rare, accounting for less than 2% of all plasma cell tumors, but it's the most common type, according to the CDC. Although the survival rate of multiple myeloma has improved in recent years, initial refractory multiple myeloma treatment is still ineffective in the vast majority of cases. If myeloma is resistant to treatment or becomes resistant during treatment, it is said to be refractory.
The refractory multiple myeloma symptoms are the same as those of multiple myeloma. These refractory multiple myeloma symptoms either persist or return after treatment. The most common refractory multiple myeloma symptom is bone pain.
Find out more about refractory multiple myeloma treatment drugs @ Drugs for Refractory Multiple Myeloma Treatment
A snapshot of the Refractory Multiple Myeloma Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Talquetamab | Janssen Research & Development, LLC | Phase III | Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants | Subcutaneous |
| Felzartamab | MorphoSys/ I-Mab Biopharma | Phase III | Antibody-dependent cell cytotoxicity; Phagocyte stimulants | Intravenous |
| RAPA-201 | Rapa Therapeutics | Phase II | Immunologic cytotoxicity; T lymphocyte replacements | Parenteral |
| PHE885 | Novartis | Phase II | Immunologic cytotoxicity; T lymphocyte replacements | Intravenous |
| CART-ddBCMA | Arcellx, Inc. | Phase II | Immunologic cytotoxicity; T lymphocyte replacements | Intravenous |
| ISB 1442 | Ichnos Sciences | Phase I/II | Antibody-dependent cell cytotoxicity; T lymphocyte stimulants | Subcutaneous |
| ALLO-605 | Allogene Therapeutics | Phase I/II | Immunologic cytotoxicity; T lymphocyte replacements | Parenteral |
| PBCAR269A | Precision Biosciences | Phase I/II | Immunologic cytotoxicity; T lymphocyte replacements | NA |
| REGN5459 | Regeneron Pharmaceuticals | Phase I/II | Antibody-dependent cell cytotoxicity; T lymphocyte stimulants | Intravenous |
| TAK-981 | Takeda | Phase I/II | Small ubiquitin-related modifier protein inhibitors | Intravenous |
| ABBV 453 | AbbVie | Phase I | Proto-oncogene protein c-bcl-2 inhibitors | Oral |
| agenT-797 | MiNK Therapeutics | Phase I | Immunologic cytotoxicity; Natural killer cell replacements | Intravenous |
Learn more about emerging refractory multiple myeloma pipeline therapies @ Refractory Multiple Myeloma Clinical Trials
Refractory Multiple Myeloma Therapeutics Assessment
The refractory multiple myeloma pipeline report proffers an integral view of the refractory multiple myeloma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Refractory Multiple Myeloma Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Ophthalmic, Intravenous, Oral, Subcutaneous, Topical, Parenteral, Transdermal
- Therapeutics Assessment By Molecule Type: Oligonucleotide, Small molecule, Peptide
- Therapeutics Assessment By Mechanism of Action: Antibody-dependent cell cytotoxicity, Cytotoxic T lymphocyte stimulants, Immunologic cytotoxicity, Small ubiquitin-related modifier protein inhibitors, Natural killer cell replacements, Proto-oncogene protein c-bcl-2 inhibitors
- Key Refractory Multiple Myeloma Companies: NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, Amgen, Pfizer, Rapa Therapeutics, Arcellx, Inc., Gilead Sciences, Novartis, Celgene Corporation, Genmab, Harpoon Therapeutics, Cytovia Therapeutics, Ichnos Sciences, Poseida Therapeutics, Allogene Therapeutics, Seagen Inc., Regeneron Pharmaceuticals, CFT7455, C4 Therapeutics, CARsgenTherapeutics Co.,Ltd, CELLECTAR BIOSCIENCES, INC., Nektar Therapeutics, iTeos Therapeutics, CASI Pharmaceuticals, Fate Therapeutics, Actinium Pharmaceuticals, Inc., Molecular Templates, Inc., NexImmune, Inc., LAVA Therapeutics, Sorrento Therapeutics, Chimerix, Ascentage Pharma Group Inc., Keymed Biosciences, MiNK Therapeutics, and others.
- Key Refractory Multiple Myeloma Pipeline Therapies: NEXI 002, AMG-701, ABBV 453, ALLO-605, PBCAR269A, TAK-981, ABBV-383, ORIC-533, agenT-797, ION251, UCARTCS1A, Y150, Talquetamab, Ipilimumab, LAVA-051, Felzartamab, Elranatamab, RAPA-201, CART-ddBCMA, Magrolimab, PHE885, Marizomib, Teclistamab, HPN-217, CYT-338, ISB 1342, P-BCMA-ALLO1, ALLO-715, ALLO-605, SEA-BCMA, REGN5458, NKTR-255, Iopofosine, EOS-448, CID-103, FT538, MT-0169, NEXI-002, LAVA-051, STI-6129, ONC201, APG-2575, CM336, agenT-797, and others.
Dive deep into rich insights for new drugs for refractory multiple myeloma treatment, visit @ Refractory Multiple Myeloma Medications
Table of Contents
| 1. | Refractory Multiple Myeloma Pipeline Report Introduction |
| 2. | Refractory Multiple Myeloma Pipeline Report Executive Summary |
| 3. | Refractory Multiple Myeloma Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Refractory Multiple Myeloma Clinical Trial Therapeutics |
| 6. | Refractory Multiple Myeloma Pipeline: Late Stage Products (Pre-registration) |
| 7. | Refractory Multiple Myeloma Pipeline: Late Stage Products (Phase III) |
| 7.1 | Talquetamab: Janssen Research & Development, LLC |
| 8. | Refractory Multiple Myeloma Pipeline: Mid Stage Products (Phase II) |
| 8.1 | PHE885: Novartis |
| 9. | Refractory Multiple Myeloma Pipeline: Early Stage Products (Phase I) |
| 9.1 | ABBV 453: AbbVie |
| 10. | Refractory Multiple Myeloma Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Refractory Multiple Myeloma Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Refractory Multiple Myeloma Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the refractory multiple myeloma pipeline therapeutics, reach out @ Refractory Multiple Myeloma Treatment Drugs
Related Reports
Relapsing Refractory Multiple Myeloma Pipeline
Relapsing Refractory Multiple Myeloma Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key relapsing refractory multiple myeloma companies, including AbbVie, Amgen, Takeda Oncology, among others.
Refractory Multiple Myeloma Market
Refractory Multiple Myeloma Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key refractory multiple myeloma companies, including Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, among others.
Refractory Multiple Myeloma Epidemiology
Refractory Multiple Myeloma Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted refractory multiple myeloma epidemiology in the 7MM.
Relapsing Refractory Multiple Myeloma Market
Relapsing Refractory Multiple Myeloma Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key relapsing refractory multiple myeloma companies, including AbbVie, Amgen, Takeda Oncology, among others.
Multiple Myeloma Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key multiple myeloma companies, including Novartis, Incyte Corporation, Arcellx, Pfizer, among others.
Multiple Myeloma Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple myeloma companies, including Novartis, Incyte Corporation, Arcellx, Pfizer, among others.
Other Trending Reports
Persistent Depressive Disorder Market | Gene Therapy for Ocular Rare Disease Market | Congestive Heart Failure Market | CRISPR Therapies Pipeline | Desmoplastic Small Round Cell Tumors Market | India Healthcare Outlook Report | Psychosis Market | Dental Lasers Market | Primary Immune Deficiency Market I Dyslipidemia Market | Lateral Epicondylitis Disease Market | Castration-Resistant Prostate Cancer Market | Metrorrhagia Market | Global Messenger RNA-based Vaccines and Therapeutics Market | Negative Pressure Wound Therapy Systems Market | US Healthcare Outlook Report | Mucinous Cystic Neoplasms Market | Hot Flashes Market | Varicose Veins - Market | Hemostats Market | Injectable Drug Delivery Devices Market | Breast Pumps Market | Physiotherapy Equipment Market | Trastuzumab Biosimilars Insight | Deep Brain Stimulation Devices Market | Retinoblastoma Market | Venous Stenosis Market | Tumor Ablation Market | Substance Abuse Market | Insulin Glargine Biosimilar Insight | Interspinous Spacers Market | Anti-hypertension Market
Related Healthcare Blogs
Multiple Myeloma Treatment Market
Related Cases Studies
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
